MEDULLARY CATECHOLAMINERGIC NEURONS IN THE NORMAL HUMAN BRAIN AND IN PARKINSONS-DISEASE

被引:75
|
作者
SAPER, CB
SORRENTINO, DM
GERMAN, DC
DELACALLE, S
机构
[1] UNIV CHICAGO, DEPT NEUROL, CHICAGO, IL 60637 USA
[2] UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA
[3] UNIV CHICAGO, BRAIN RES INST, CHICAGO, IL 60637 USA
[4] UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DALLAS, TX 75230 USA
[5] UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75230 USA
[6] UNIV NAVARRA, DEPT ANAT, PAMPLONA, SPAIN
关键词
D O I
10.1002/ana.410290602
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease is thought to cause degeneration of melanin-pigmented catecholaminergic neurons throughout the brainstem, but little quantitative information is available on the fate of catecholaminergic neurons associated with the dorsal vagal complex or medullary reticular formation. We therefore examined these neurons in the normal human medulla and in the brains of patients with Parkinson's disease, using both a melanin stain and immunohistochemical methods with an antiserum against tyrosine hydroxylase. The greatest numbers of catecholaminergic neurons in the ventrolateral reticular formation (A1/C1 group) were located in the far rostral medulla, whereas the largest populations of catecholaminergic cells in the dorsal vagal complex (A2/C2 group) were found at the level of the area postrema. No loss of cells was observed in the A1/C1 group in the parkinsonian brains. In contrast, the A2/C2 group showed moderate loss of neurons, most marked at the level of the area postrema. This difference was entirely due to the loss of neurons in the medial component of the A2 group, a population that normally is only lightly pigmented, while the heavily pigmented neurons in the ventral and intermediate components of the A2 complex were unaffected. Parkinson's disease causes degeneration only of selected populations of medullary catecholaminergic neurons, without apparent relationship to the extent of melanin pigmentation.
引用
收藏
页码:577 / 584
页数:8
相关论文
共 50 条
  • [21] NEUROPSYCHOLOGICAL EFFECTS OF BRAIN AUTOGRAFT OF ADRENAL-MEDULLARY TISSUE FOR THE TREATMENT OF PARKINSONS-DISEASE
    OSTROSKYSOLIS, F
    QUINTANAR, L
    MADRAZO, I
    DRUCKERCOLIN, R
    FRANCOBOURLAND, R
    LEONMEZA, V
    NEUROLOGY, 1988, 38 (09) : 1442 - 1450
  • [22] TRANSPLANTATION OF FETAL DOPAMINE NEURONS IN PARKINSONS-DISEASE
    ODIN, P
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 1992, 27 (3-4) : 408 - 408
  • [23] BRAIN GRAFTING AS A TREATMENT FOR PARKINSONS-DISEASE
    PERLOW, MJ
    NEUROSURGERY, 1987, 20 (02) : 335 - 342
  • [24] PARKINSONS-DISEASE - BRAIN DOPAMINE RECEPTORS
    LEE, T
    SEEMAN, P
    RAJPUT, A
    FARLEY, I
    HORNYKIEWICZ, O
    FEDERATION PROCEEDINGS, 1978, 37 (03) : 382 - 382
  • [25] NEUROPHYSIOLOGICAL PROPERTIES OF PALLIDAL NEURONS IN PARKINSONS-DISEASE
    STERIO, D
    BERIC, A
    DOGALI, M
    FAZZINI, E
    ALFARO, G
    DEVINSKY, O
    ANNALS OF NEUROLOGY, 1994, 35 (05) : 586 - 591
  • [26] PARKINSONS-DISEASE, MRI, AND BRAIN IRON
    LUDWIG, CL
    WEINBERGER, DR
    WENER, L
    CHASE, TN
    NEUROLOGY, 1986, 36 (04) : 244 - 244
  • [27] BRAIN NEUROTRANSMITTERS AND NEUROPEPTIDES IN PARKINSONS-DISEASE
    RINNE, UK
    RINNE, JO
    RINNE, JK
    LAAKSO, K
    LONNBERG, P
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA LATINOAMERICANA, 1984, 34 (03): : 287 - 299
  • [28] BRAIN TARGETS IN PARKINSONS-DISEASE SURGERY
    VAJDA, J
    TOTH, S
    JOURNAL OF NEUROSURGERY, 1985, 63 (03) : 478 - 478
  • [29] COURSE OF BRAIN ATROPHY IN PARKINSONS-DISEASE
    SCHNEIDER, E
    BECKER, H
    FISCHER, PA
    GRAU, H
    JACOBI, P
    BRINKMANN, R
    ARCHIV FUR PSYCHIATRIE UND NERVENKRANKHEITEN, 1979, 227 (01): : 89 - 95
  • [30] FETAL BRAIN GRAFTS AND PARKINSONS-DISEASE
    MILETICH, RS
    BANKIEWICZ, KS
    PLUNKETT, RJ
    SCIENCE, 1990, 250 (4986) : 1434 - 1435